Africa CDC & WHO Roll Out Joint Continental Ebola Response Strategy

The Africa Centres for Disease Control and Prevention (Africa CDC) & the World Health Organization (WHO) unveiled a joint continental preparedness and response plan on the ongoing Ebola outbreak due to the Bundibugyo virus. This plan mainly focuses on raising US$518 million to assist African countries, along with partners, to prepare for, quickly find & respond to the outbreak. 

Respective plan is made from June to November 2026, assembling governments, partners & communities under an integrated ‘One Response’ approach to empower outbreak response solutions, such as emergency coordination, disease surveillance, laboratory testing, infection prevention & control, clinical care, community involvement, research, logistics & assistance for essential health services. 

Dr Tedros Adhanom Ghebreyesus, WHO Director-General, stated that to beat this outbreak, this was the only solution, that covers a strong alliance, working together under the leadership of the affected countries in one coordinated effort, supported by a simple principle, i.e. one plan, one budget, one team. 

About Africa CDC 

The Africa Centres for Disease Control and Prevention (Africa CDC) is the public health agency of the African Union, which is an autonomous institution. This prominently fosters AU Member States to expand health systems, enhance disease surveillance, & optimize emergency preparedness and response. 

About WHO  

The WHO (World Health Organization) is devoted to the well-being of all people & assisted by science, the WHO leads and champions global efforts to facilitate everyone, everywhere an equal chance at a safe & healthy life. 

According to Towards Healthcare, the Middle East and Africa central lab market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 198.04 million in 2026 to approximately USD 468.68 million by 2035, representing a compound annual growth rate (CAGR) of 10.04% from 2026 to 2035.Continuous expansion is primarily driven by increasing burden of chronic and infectious diseases, major growth in geographical clinical trials, & proactive government investments in healthcare infrastructure & digitalization. 

Emerging Opportunities Across the LDTs & Clinical Trials  

In the coming era, the Middle East and Africa central lab market will promote greater investment in clinical trial infrastructure & regulatory streamlining to unite with global Good Clinical Practice (GCP) standards, specifically in the UAE, Saudi Arabia, & Qatar.  

Alongside, to meet the growing demand for tailored diagnostics for rare diseases and ideal regional epidemiology patterns, speciality diagnostics labs in the region will increasingly transform to establish custom testing protocols. 

According to Towards Healthcare, the Middle East and Africa central lab market is anticipated to grow steadily, supported by increasing clinical trial activity, expanding pharmaceutical and biotechnology research, improving healthcare infrastructure, rising demand for standardized laboratory testing, and greater investments in precision medicine initiatives.